
References

- Abdool Karim S.S., Naidoo K, Grobler A., Padayatchi N, Baxter C., Gray A, et al., (2010):** Timing of initiation of antiretroviral drugs during tuberculosis therapy N Engl J Med. Feb 25; 362 (8): 697-706.
- Al-Awaidy S., et al., (2010):** Surveillance of adverse events following immunization 10 years experience in Oman, EMHJ. Vol. 16 P.5.
- Aronson NE, Santosham M, Comstock GW (2004):** "Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study". JAMA 291 (17): 2086-91.
- Asensio JA, Arbues A, Perez E, Gicquel B, Martin C., (2008):** Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials. *Expert Opin Biol Ther.* Feb;8(2):201-11.
- Ashley M.J., Siebenmann C.O., (2000):** Tuberculin skin sensitivity following BCG vaccination with vaccines of high and low viable counts can med Assoc J 97: 1335-1338.
- Awad R., et al., (2001):** BCG vaccine and post-BCG complications among infants in Gaza strip, Eastern Mediterranean Health Journal. Vol. 7. Nos 1-2.
- BBC News, (2011):** "Tuberculosis vaccine target found" 19 March.
- Becerra M.C., Appleton S.C., Franke M.F., Chalco K., Arteaga F., Bayona J., et al., (2011):** Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. Jan 8; 377 (9760): 147-52.
- Black GF, Weir RE, Floyd S (2002):** "BCG-induced increase in

interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malai and the UK: two randomized controlled studies". *Lancet* 359 (9315): 1393-401.

Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al., (2010): Rapid molecular detection of tuberculosis and rifampin resistance. *N Engl J Med.* Sep 9; 363(11): 1005-15.

Brandt L, Feino Cunha J, Weinreich Olsen A (2002): "Failure of *Mycobacterium bovis* BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis". *Infect Immune* 70 (2): 672- 78.

Brassard P, Suissa S, Kezouh A, Ernst P., (2010): Inhaled Corticosteroids and Risk of Tuberculosis in Patients with Respiratory Diseases. *Am J Respir Crit Care Med.*

Brosch R, Gordon SV, Gamier T, Eiglmeier K (2007): "Genome plasticity of BCG and impact on vaccine efficacy" *proc Natl Acad Sci* 104 (13): 5595. 601.

Brown M, Varia H, Bassett P, Davidson RN, Wall R, Pasvol G., (2007): Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. *Clin Infect Dis.* Jun; 44(11):1415-20.

Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, et al., (2006): Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. *Am J Respir Crit Care Med.* Aug 1;174(3):331-8.

CDC, (2010): Targeted tuberculin testing and treatment of latent tuberculosis infection American Thoracic Society. *MMWR*

- Recomm Rep. Jun 9; 49: 1-51.
- CDC, (2011):** Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection MMWR; 60: 1950-1653.
- CDC. (2009):** Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. *MMWR Recomm Rep.* Feb 13;58:1.
- CDC. Trends in tuberculosis-United States, (2008):** MMWR Morb Mortal Wkly Rep. Mar 20; 58(10):249-53.
- Centers for Disease control and prevention (CDC), (2003):** Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS) United states, Morbidity and mortality weekly report, 52 (1):1-24.
- Centers for Disease Control and Prevention., (2008):** Managing Drug Interactions in the treatment of HIV- Related Tuberculosis. CDC. Available at [http:// ww. Cdc. Gov/tb/TB-HIV-Drugs/default.htm](http://www.Cdc.Gov/tb/TB-HIV-Drugs/default.htm). Accessed 08/20.
- Chen R.T., Davis R.L., Sheedy K.M., (2004):** Safety of immunizations in vaccines (4th Edition). Philadelphia. WB saunders. 2004 pp 1557-1575.
- Choi J.H., Lee K.W., Kang H.R., Hwang Y.L, Jang S., Kim D.G., et al., (2010):** Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a cli9nical setting. *Chest.* Feb; 137 (2): 393-400.
- Colditz GA, Brewer TF, Berkey CS (2005):** "Efficacy of BCG Vaccine in the Prevention of Tuberculosis". *J Am Med Assoc* 271(9): 698-702.
- Comstock GW, Palmer CE. (2007):** "Long-term results of BCG in the

- southern United States". Am Rev Resp Dis 93 (2): 171-83.
- Daily Mail (London), (2008):** "Human trials to begin on diabetes cure after terminally ill mice are returned to health" 14 March.
- Diacon A.H., Pym A., Grobusch M., Patient R., Rustomjee R., Page Shipp L, et al., (2009):** the diarylquinoline TMC 207 for multidrug-resistant tuberculosis. N Engl J Med. Jun 4; 360 (23): 2397-405.
- (EPI) Expanded Programme on Immunization Biologicals Unit (2000):** BCG associated lymphadenitis in infants. Wkly Epidemiol Rec 30: 231-232.
- Fine PEM, Carneiro IAM, Milstein JB, Clements CJ. (1999):** Issues relating to the use of BCG in immunization programs. Geneva: WHO.
- Goldman K.P., (2000):** Treatment of Local complications of BCG vaccination. Tubercle; 66: 158-9.
- Govindarajan KK, Chai FY (2011):** "BCG adenitis - need for increased awareness". Mai J Med Sci 18 (2): 67-70.
- Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al., (2001):** Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. Oct 11; 345(15): 1098-104.
- Kim S.H., Lee S.O., Park J.B., park I.A., park S.J., Yun S.C., et al., (2011):** A prospective Longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J transplant. Sep: 11 (9): 1927-35.
- Lamm DL, Blumenstein BA, Crawford ED (1999):** "A randomized trial of intravesical Doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the

bladder". N Engl J Med 325 (2): 1205.

Lawrence G, et al., (2005): Surveillance of adverse events following immunization in Australia. Communicable diseases intelligence, 29 (3): 248-62.

Leung CC, Lam TH, Chan WM, Yew WW, Ho KS, Leung G, et al., (2007): Lower risk of tuberculosis in obesity. Arch Intern Med. Jun 25; 167(12):1297-304.

Leung CC, Yam WC, Yew WW, Ho PL, Tarn CM, Law WS, et al., (2010): T-Spot. TB outperforms tuberculin skin test in predicting tuberculosis disease. Am J Respir Crit Care Med. Sep 15; 182(6):834-40.

Lotte A, Wasz-Hockert O, poisson N, Dumitrescu N, Verron M, couvet E.,(1999): BCG complications Advances in Tuberculosis Research 21: 107-93.

Mahler HT, Mohamed Ali P (2000): "Review of mass BCG. project in India". Ind J Tuberculosis 2 (3): 108-16.

Manuel O, Humar A, Preiksaitis J, Doucette K, Shokoples S, Peleg AY, et al., (2007): Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant. Dec;7(12):2797-801.

Mazurek G.H., Jereb J., Vernon A., Lo Bue P., Goldberg S., Castro K, et al., (2010): Updated guidelines for using interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection- united states, MMWR Recomm Rep. Jun 25; 59: 1-25.

Mazurek GH, Weis SE, Moonan PK, Daley CL, Bernardo J, Lardizabal AA, et al., (2007): Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma

release assays in persons with suspected tuberculosis. *Clin Infect Dis.* Oct 1; 45(7):837-45.

Menzies D, Joshi R, Pai M., (2007): Risk of tuberculosis infection and disease associated with work in health care settings. *Int J Tuberc Lung Dis.* Jun; 11(6):593- 605.

Minion J, Leung E, Menzies D, Pai M., (2010): Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. *Lancet Infect Dis.* Oct; 10(10):688-98.

Ministry of Health, Oman, (2000): Hypersensitivity reactions reported with MR vaccine. *Community health and disease surveillance newsletter*, 4 (3): 7-8.

Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, Marais E., (2008): Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. *Int J Tuberc Lung Dis.* Jan;12(1):99-104.

Moran GJ, McCabe F, Morgan MT, Talan DA., (1995): Delayed recognition and infection control for tuberculosis patients in the emergency department. *Ann Emerg Med.* Sep; 26(3):290-5.

Mosolits S, Nilsson B, Millstadt H. (2005): "Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials". *Expert Rev Vaccines* 4 (3): 329-50.

Muga R, Ferreros I, Langohr K, de Olalla PG, Del Romero J, Quintana M, et al., (2007): Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. *AIDS.* Nov 30; 21(18):2521-7.

National Report (interim) on immunization vaccine safety issues and surveillance.(2000): Reported adverse events temporarily

associated with vaccine administration in Canada. Journal of the Canadian pediatric society, 30: 319-33.

Nick Makwana and Andrew Riordan (2004): "Is medical therapy effective in the treatment of BCG abscesses?", Birmingham Heartlands Hospital

Orme L.M., Memurray D.N., Beliste J.T., (2001): Tuberculosis vaccine development recent progress trends microbial 9: 115-118.

Packe GE, Innes JA. (2008): "Protective effect of BCG vaccination in infant Asians: Archives of Disease in Childhood 63 (3): 277-281.

Plotkin M., Dantor L.N., Colaiacovo D., et al., (2004): Evaluation of the effectiveness of BCG vaccination using the case-control.

Prakash M., Jecna et al., (2004): Safety of the intradermal Copenhagen 1331 BCG vaccine in Neonates in Durban-South Africa, Bulletin of the WHO. 79: 337-343.

Prakash M.J., et al., (2001): Safety of the intra-dermal Copenhagen 1331 BCG vaccine in neonates in Durban, south Africa. Bulletin of World Health organization, 79 (4): 337-43.

Ristori G, Buzzi M.G., Sabatini U., Giugni E., Baastianello S., Viselli F., Buttinelli C., Rugieri S., Colonnese C., Pozzilli C., Saivetti M, (2000):"Use of Bacille calmette-Guerin (BCG) in multiple sclerosis". Neurology 53 (7):1588-1589.

Rodrigues LC, Diwan VK, Wheeler JG (2008): "Protective Effect of BCG against Tuberculous Meningitis and Miliary Tuberculosis: A Meta-Analysis". IntJ Epidemiol22 (6): 1154-58.

Rosenthal SR. (1997): BCG vaccination against tuberculosis. Boston: Litte, Brown & Co.

- Rutschmann, OT; McCrory, DC; Matchar, DB; (2002):** Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines "Immunization and MS: a summary of published evidence and recommendations". *Neurology* 59 (12): 1837-1843.
- Schuurmans MM, Ellmann A, Bouma H, Diacon AH, Dyckmans K, Bolliger CT., (2007):** Solitary pulmonary nodule evaluation with 99mTc-methoxy isobutyl isonitrile in a tuberculosis-endemic area. *EurRespirJ*. Dec; 30(6): 1090-5.
- Setia MS, Steinmaus C, Ho CS, Rutherford GW., (2006):** "The role of BCG in prevention of leprosy: a meta-analysis". *Lancet Infect D/s6* (3): 162-70.
- Slama K, Chiang CY, Enarson DA, Hassmiller K, Fanning A, Gupta P, et al., (2007):** Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. *IntJ Tuberc Lung Dis*. Oct; 11 (10): 1049-61.
- Sokolove PE, Lee BS, Krawczyk JA, Banos PT, Gregson AL, Boyce DM, et al., (2000):** Implementation of an emergency department triage procedure for the detection and isolation of patients with active pulmonary tuberculosis. *Ann Emerg Med*. Apr; 35(4):327-36.
- Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S., (2005):** How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. *J Infect Dis*. Jan 15; 191(2):150-8.
- Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, et al., (2011):** Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and

- Canada: Implications for Tuberculosis Screening. *J Infect Dis.* Sep; 204(6):893-901.
- Styblo K, Meijer J. (1999):*** "Impact of BCG vaccination programs in children and young adults on the tuberculosis problem". *Tubercle* 57: 17-43.
- Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Menon P.A, et al., (2010):*** Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. *Am J Respir Crit Care Med.* Apr; 18 (7): 743-51.
- Szczuka et al., (2002):*** Adverse events following immunization with BCG vaccine in Poland, *Przegl Epidemiol*, (2): 205-16.
- Szczuka I., (2000):*** Adverse events after BCG vaccination in Poland *Pneumonologia I alergologia polska*, 67 (5-6): 208-16.
- Tanghe, A., J. Content, J. P. Van Vooren, F. Portaels, and K. Huygen (2001):*** "Protective efficacy of a DNA vaccine encoding antigen 85A from *Mycobacterium bovis* BCG against Buruli ulcer". *Infect Immun* 69 (9): 5403.
- Trunz BB, Fine P, Dye C (2006):*** "Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness". *Lancet* 367 (9517): 1173-1180.
- Verhagen LM, van den Hof S, van Deutekom H, Hermans PW, Kremer K, Borgdorff MW, et al., (2011):*** Mycobacterial factors relevant for transmission of tuberculosis. *J Infect Dis.* May; 203(9):1249-55.
- Vieites B, Suarez-Penaranda JM, Perez Del Molino ML, Vazquez-Veiga H, Pardo F, Del Rio E, et al., (2005):*** Recovery of *Mycobacterium tuberculosis* DNA in biopsies of erythema

induratum-results in a series of patients using an improved polymerase chain reaction technique. *BrJ Dermatol.* Jun 2005; 152(6): 1394-6.

Waitt CJ, Peter K Banda N, White SA, Kampmann B, Kumwenda J, Heyderman RS, et al., (2011): Early deaths during tuberculosis treatment are associated with depressed innate responses, bacterial infection, and tuberculosis progression. *J Infect Dis.* Aug; 204(3):358-62.

Weir R.F., Gorak-Stolinska P., Floyd S., Lalor M.K., Stenson S., Branson K., et al., (2008): persistence of the immune response induced by BCG vaccination. *BMC infect Dis.* Jan 25; 8-9.

Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, et al., (2007): HIV infection and multidrug-resistant tuberculosis: the perfect storm. *J Infect Dis.* Aug 15 ;196 Suppl 1:586-107.

WHO (2004): WHO Position Paper on BCG Vaccination . Geneva: WHO.

WHO, (1999): Surveillance of adverse events following immunization field guide for managers of immunization programmers. Geneva.

WHO.,Global tuberculosis control (2010): surveillance, planning, financing. World Health Organization. Available at <http://www.who.int/publication/tuberculosis/en/>. Accessed jan 21.

World Health Organization, (2001): BCG in immunization programmes *wkly Epidemiol Rec* 76: 33-40.

World Health Organization. (2008): Antituberculosis drug resistance in the world. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance WHO. Geneva;

1-120.

World Health Organization. Global tuberculosis control (Control, 2010): orld Health Organization. Available at [http/ www. who. inytb/ publications/ globaLreport/ en/index.html](http://www.who.int/tb/publications/globalreport/en/index.html). Accessed Jan 21, 2011.

Yong, J; Goran Lacan, Hoa Dang, Terry Hsieh, Blake Middleton, Clive Wasserfall, JideTian, William P. Melega, Daniel L, Kaufman (2011): "BCG Vaccine-Induced Neuroprotection in a Mouse Model of Parkinson's Disease". PLoS ONE. PMID 21304945.

Zhongguo Y.I., et al., (2009): Analysis on the surveillance of adverse events following immunization in china, Department of National immunization program, Chinese center for disease control and prevention, Beijing 100050, china. Dec; 15 (6): 481-90.

Zhongguo Y.I., et al., (2009): Literature review of adverse events following immunization of Bacillus calemtte-guerin vaccine. Department of National immunization program, Chinese center for disease control and prevention, Beijing 100050, china. Dec; 15 (6): 491-5.